Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team March 8, 2023
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate March 1, 2023
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate December 22, 2022
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate August 24, 2022
